Antihypertensive treatment in diabetic patients. Review of current data

Maturitas

Volumn 75, Issue 2, 2013, Pages 142-147

  Argyrakopoulou, Georgia ^a   Tsioufis, Costas ^b   Sdraka, Eleni ^a   Tsiachris, Dimitris ^b   Makrilakis, Konstantinos ^a   Stefanadis, Christodoulos ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Diabetes; Hypertension; Targets; Treatment

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIURETIC AGENT; PETROLEUM;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; DIABETIC NEPHROPATHY; DIABETIC PATIENT; HUMAN; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYSTOLIC BLOOD PRESSURE;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIABETES COMPLICATIONS; DIABETES MELLITUS; HUMANS; HYPERTENSION; RENIN-ANGIOTENSIN SYSTEM;

EID: 84877838717     PISSN: 03785122     EISSN: 18734111     Source Type: Journal    
DOI: 10.1016/j.maturitas.2013.03.012     Document Type: Review

References (42)

1. J.R. Sowers, M. Epstein, and E.D. Frohlich Diabetes, hypertension, and cardiovascular disease: an update Hypertension 37 2001 1053 1059
2. S. Wild, G. Roglic, A. Green, R. Sicree, and H. King Global prevalence of diabetes: estimates for the year 2000 and projections for 2030 Diabetes Care 27 2004 1047 1053
3. UKPDS Hypertension in Diabetes Study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications Journal of Hypertension 11 1993 309 317
4. A.V. Chobanian, G.L. Bakris, and H.R. Black The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report Journal of American Medical Association 289 2003 2560 2572
5. G. Mancia, G. De Backer, and A. Dominiczak Management of arterial hypertension of the European Society of Hypertension; European Society of Cardiology 2007 guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) Journal of Hypertension 25 2007 1105 1187
6. G. Mancia, S. Laurent, and E. Agabiti-Rosei Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document Journal of Hypertension 27 2009 2121 2158
7. F. Turnbull, B. Neal, and C. Algert Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials Archives of Internal Medicine 165 2005 1410 1419
8. The fifth report of the Joint National Committee on Detection Evaluation, and Treatment of High Blood Pressure (JNC V) Archives of Internal Medicine 153 1993 154 183
9. L. Hansson, A. Zanchetti, and S.G. Carruthers Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial HOT Study Group Lancet 351 1998 1755 1762
10. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 UK Prospective Diabetes Study Group British Medical Journal 317 1998 703 713
11. ACCORD Study Group, W.C. Cushman, and G.W. Evans Effects of intensive blood-pressure control in type 2 diabetes mellitus New England Journal of Medicine 362 2010 1575 1585
12. R.M. Cooper-DeHoff, Y. Gong, and E.M. Handberg Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease Journal of American Medical Association 304 2010 61 68
13. J.D. Curb, S.L. Pressel, and J.A. Cutler Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension Systolic Hypertension in the Elderly Program Cooperative Research Group Journal of American Medical Association 276 1996 1886 1892
14. J. Tuomilehto, D. Rastenyte, and W.H. Birkenhäger Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension Systolic Hypertension in Europe Trial Investigators New England Journal of Medicine 340 1999 677 684
15. A. Patel, S. MacMahon, and J. Chalmers Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial Lancet 370 2007 829 840
16. R.R. Holman, S.K. Paul, M.A. Bethel, H.A. Neil, and D.R. Matthews Long-term follow-up after tight control of blood pressure in type 2 diabetes New England Journal of Medicine 359 2008 1565 1576
17. R.O. Estacio, B.W. Jeffers, W.R. Hiatt, S.L. Biggerstaff, N. Gifford, and R.W. Schrier The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension New England Journal of Medicine 338 1998 645 652
18. R.W. Schrier, R.O. Estacio, A. Esler, and P. Mehler Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes Kidney International 61 2002 1086 1097
19. T. Berl, L.G. Hunsicker, and J.B. Lewis Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial Journal of the American Society of Nephrology 16 2005 2170 2179
20. American Diabetes Association Standards of medical care in diabetes - 2013 Diabetes Care 36 2013 S11 S66
21. I. Eleftheriadou, C. Tsioufis, D. Tsiachris, N. Tentolouris, and C. Stefanadis Choice of antihypertensive treatment in subjects with pre-diabetes. Is there a dream after the navigator Current Vascular Pharmacology 9 2011 715 722
22. L. Hansson, L.H. Lindholm, and L. Niskanen Effect of angiotensin- converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial Lancet 353 1999 611 616
23. S. Yusuf, H. Gerstein, and B. Hoogwerf Ramipril and the development of diabetes Journal of American Medical Association 286 2001 1882 1885
24. E. Vermes, A. Ducharme, M.G. Bourassa, M. Lessard, M. White, and J.C. Tardif Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies of Left Ventricular Dysfunction (SOLVD) Circulation 107 2003 1291 1296
25. S. Yusuf, J.B. Ostergren, and H.C. Gerstein Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure Circulation 112 2005 48 53
26. L.H. Lindholm, M. Persson, P. Alaupovic, B. Carlberg, A. Svensson, and O. Samuelsson Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study) Journal of Hypertension 21 2003 1563 1574
27. S.E. Kjeldsen, G.T. McInnes, and G. Mancia Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: the VALUE trial Blood Pressure 17 2008 170 177
28. L.H. Lindholm, H. Ibsen, and B. Dahlöf Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol Lancet 359 2002 1004 1010
29. L.H. Lindholm, H. Ibsen, and K. Borch-Johnsen Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study Journal of Hypertension 20 2002 1879 1886
30. NAVIGATOR Study Group, J.J. McMurray, and R.R. Holman Effect of valsartan on the incidence of diabetes and cardiovascular events New England Journal of Medicine 362 2010 1477 1490
31. C.J. Pepine, E.M. Handberg, and R.M. Cooper-DeHoff A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial Journal of American Medical Association 290 2003 2805 2816
32. A.K. Gupta, B. Dahlöf, J. Dobson, P.S. Sever, H. Wedel, and N.R. Poulter Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial - Blood Pressure Lowering Arm and the relative influence of antihypertensive medication Diabetes Care 31 2008 982 988
33. S. Jacob, K. Rett, M. Wicklmayr, B. Agrawal, H.J. Augustin, and G.J. Dietze Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study Journal of Hypertension 14 1996 489 494
34. C. Torp-Pedersen, M. Metra, and A. Charlesworth Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET) Heart 93 2007 968 973
35. E. Agabiti Rosei, and D. Rizzoni Metabolic profile of nebivolol, a beta-adrenoceptor antagonist with unique characteristics Drugs 67 2007 1097 1107
36. M.B. Murphy, P.J. Lewis, E. Kohner, B. Schumer, and C.T. Dollery Glucose intolerance in hypertensive patients treated with diuretics; a fourteen-year follow-up Lancet 2 1982 1293 1295
37. G. Berglund, O. Andersson, and B. Widgren Low-dose antihypertensive treatment with a thiazide diuretic is not diabetogenic. A 10-year controlled trial with bendroflumethiazide Acta Medica Scandinavica 220 1986 419 424
38. G. Mancia, M. Brown, and A. Castaigne Outcomes with nifedipine GITS or co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT) Hypertension 41 2003 431 436
39. J.I. Barzilay, B.R. Davis, and J.A. Cutler Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Archives of Internal Medicine 166 2006 2191 2201
40. K. Jamerson, M.A. Weber, and G.L. Bakris Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. ACCOMPLISH Trial Investigators New England Journal of Medicine 359 2008 2417 2428
41. ONTARGET Investigators, S. Yusuf, and K.K. Teo Telmisartan, ramipril, or both in patients at high risk for vascular events New England Journal of Medicine 358 2008 1547 1559
42. H.H. Parving, B.M. Brenner, and J.J. McMurray Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE) Journal of the Renin-Angiotensin-Aldosterone System 13 September (3) 2012 387 393